Working… Menu

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03634059
Recruitment Status : Unknown
Verified July 2018 by LiuJunFeng, Hebei Medical University Fourth Hospital.
Recruitment status was:  Not yet recruiting
First Posted : August 16, 2018
Last Update Posted : August 16, 2018
Information provided by (Responsible Party):
LiuJunFeng, Hebei Medical University Fourth Hospital

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : August 15, 2019
Estimated Study Completion Date : August 15, 2020